Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Intercure ( (IL:INCR) ) has shared an announcement.
InterCure has received a Nasdaq notice that its ordinary shares have traded below the $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq’s listing rules. The company has until August 24, 2026, to restore its share price to at least $1.00 for 10 straight trading days, with the possibility of an additional 180-day extension if it meets other listing criteria.
Management is monitoring the share price and is considering a reverse share split, subject to necessary approvals, as part of its plan to regain compliance while continuing to advance business and strategic initiatives. InterCure’s shares will remain listed and tradable on the Nasdaq Global Market during the grace period, but failure to meet the minimum bid requirement within the allowed timeframe could ultimately result in delisting, a risk closely watched by investors and other stakeholders.
The most recent analyst rating on (IL:INCR) stock is a Sell with a ILs283.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.
More about Intercure
InterCure Ltd., which operates as Canndoc, is a leading and profitable cannabis company outside North America, focused on pharmaceutical-grade medical cannabis. Through its wholly owned subsidiary Canndoc, it is Israel’s largest licensed cannabis producer, leveraging a vertically integrated seed-to-sale model and international partnerships to serve the rapidly growing global medical cannabis market.
Average Trading Volume: 115,388
Technical Sentiment Signal: Sell
Current Market Cap: ILs144.6M
Learn more about INCR stock on TipRanks’ Stock Analysis page.